Korro Bio Inc
NASDAQ:KRRO

Watchlist Manager
Korro Bio Inc Logo
Korro Bio Inc
NASDAQ:KRRO
Watchlist
Price: 43.67 USD 1.28%
Market Cap: 409.2m USD
Have any thoughts about
Korro Bio Inc?
Write Note
KRRO
/
Income Statement
/
Cost of Revenue

Korro Bio Inc
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Korro Bio Inc
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Korro Bio Inc
NASDAQ:KRRO
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cost of Revenue
-$18.2B
CAGR 3-Years
-1%
CAGR 5-Years
-19%
CAGR 10-Years
-15%
Gilead Sciences Inc
NASDAQ:GILD
Cost of Revenue
-$6.3B
CAGR 3-Years
-5%
CAGR 5-Years
-7%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Cost of Revenue
-$12.9B
CAGR 3-Years
-27%
CAGR 5-Years
-25%
CAGR 10-Years
-13%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cost of Revenue
-$1.5B
CAGR 3-Years
-20%
CAGR 5-Years
-25%
CAGR 10-Years
-36%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cost of Revenue
-$1.8B
CAGR 3-Years
0%
CAGR 5-Years
-22%
CAGR 10-Years
-25%
No Stocks Found

Korro Bio Inc
Glance View

Market Cap
406.9m USD
Industry
Biotechnology

Korro Bio Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Cambridge, Massachusetts and currently employs 48 full-time employees. The company went IPO on 2019-10-03. Korro Bio, Inc. is a biopharmaceutical company. The firm discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The firm is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Its Oligonucleotide Promoted Editing of RNA (OPERA) is a foundational platform for RNA editing, which is designed to edit RNA in vivo by delivering an oligonucleotide guide that can target specific RNA sequences. OPERA co-opts the cell’s natural process with its synthetic oligo and catalyzes a single base change to modify protein sequence and function without the need to permanently modify one’s genome. The firm's focus areas include the liver and central nervous system (CNS).

KRRO Intrinsic Value
17.73 USD
Overvaluation 59%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.